Skip to Main Content
Contribute Try STAT+ Today

Amid controversy over equitable distribution of Covid-19 vaccines, a large coalition of socially minded investor groups has filed shareholder proposals urging large drug makers to take various steps that could ultimately widen access to their medicines in the U.S. and elsewhere.

The effort reflects ongoing frustration with the pharmaceutical industry over business practices that have often made it difficult for patients to obtain treatments, according to Meg Jones-Monteiro, program director for health equity at the Interfaith Center on Corporate Responsibility, a 300-member organization with combined assets of over $4 trillion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment